TW202334176A - 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 - Google Patents

新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 Download PDF

Info

Publication number
TW202334176A
TW202334176A TW111142076A TW111142076A TW202334176A TW 202334176 A TW202334176 A TW 202334176A TW 111142076 A TW111142076 A TW 111142076A TW 111142076 A TW111142076 A TW 111142076A TW 202334176 A TW202334176 A TW 202334176A
Authority
TW
Taiwan
Prior art keywords
compound
immunoconjugate
group
methyl
mmol
Prior art date
Application number
TW111142076A
Other languages
English (en)
Chinese (zh)
Inventor
理察 H 李
東駿 李
Original Assignee
美商艾德森特克斯治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾德森特克斯治療股份有限公司 filed Critical 美商艾德森特克斯治療股份有限公司
Publication of TW202334176A publication Critical patent/TW202334176A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111142076A 2021-11-03 2022-11-03 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 TW202334176A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US63/275,177 2021-11-03
US202163295476P 2021-12-30 2021-12-30
US63/295,476 2021-12-30

Publications (1)

Publication Number Publication Date
TW202334176A true TW202334176A (zh) 2023-09-01

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142076A TW202334176A (zh) 2021-11-03 2022-11-03 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物

Country Status (10)

Country Link
US (1) US20260131016A1 (enExample)
EP (1) EP4426714A4 (enExample)
JP (1) JP2024540402A (enExample)
KR (1) KR20240110584A (enExample)
AU (1) AU2022380491A1 (enExample)
CA (1) CA3236944A1 (enExample)
IL (1) IL312533A (enExample)
MX (1) MX2024005342A (enExample)
TW (1) TW202334176A (enExample)
WO (1) WO2023081230A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786483A1 (en) 2023-09-26 2026-08-05 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Auristatin derivative and antibody-drug conjugate thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
KR20240110584A (ko) 2024-07-15
EP4426714A1 (en) 2024-09-11
AU2022380491A1 (en) 2024-05-30
MX2024005342A (es) 2024-09-27
WO2023081230A1 (en) 2023-05-11
CA3236944A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
US20260131016A1 (en) 2026-05-14
JP2024540402A (ja) 2024-10-31
IL312533A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP2024038168A (ja) 生物活性分子コンジュゲート、その調製法及び使用
CA2852860C (en) Cytotoxic peptides and antibody drug conjugates thereof
RS64961B1 (sr) Derivati kamptotecina
TWI712605B (zh) 含有cti藥效基團之雙功能性細胞毒性劑
JP2020512270A (ja) ピロロベンゾジアゼピン二量体前駆体及びそのリガンド−リンカーコンジュゲート化合物
ES2867749T3 (es) Conectores y su aplicación con respecto a los CAF
CA3027178A1 (en) Anti-egfr antibody drug conjugates
EP3907226A2 (en) Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
AU2024263367A1 (en) Antibody-drug conjugate
TW202426456A (zh) 新穎的喜樹鹼類似物及其免疫綴合物
JP2018123122A (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
CA3198230A1 (en) Conjugate and use thereof
WO2024193692A1 (zh) 连接子及其在配体药物偶联物中的应用
WO2024160176A1 (zh) 一类连接子药物及其抗体-药物偶联物的制备方法和应用
TW202400266A (zh) 配體藥物偶聯物及其應用
US20260131016A1 (en) Novel auristatin analogs and immunoconjugates thereof
TW202328162A (zh) 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物
CN120957756A (zh) 稠环化合物及其制备方法和用途
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40115429A (en) Novel auristatin analogs and immunoconjugates thereof
HK40117241A (en) Novel auristatin analogs and immunoconjugates thereof
WO2026065268A1 (en) Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same
CN120513102A (zh) 一种抗体药物偶联物及其制备方法和用途